Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The survival rate of patients with breast cancer has been improved by immune checkpoint blockade therapies, and the efficacy of their combinations with epigenetic modulators has shown promising results in preclinical studies. In this prospective study, we propose an ordinary differential equation (ODE)-based quantitative systems pharmacology (QSP) model to conduct an in silico virtual clinical trial and analyze potential predictive biomarkers to improve the anti-tumor response in HER2-negative breast cancer. The model is comprised of four compartments: central, peripheral, tumor, and tumor-draining lymph node, and describes immune activation, suppression, T cell trafficking, and pharmacokinetics and pharmacodynamics (PK/PD) of the therapeutic agents. We implement theoretical mechanisms of action for checkpoint inhibitors and the epigenetic modulator based on preclinical studies to investigate their effects on anti-tumor response. According to model-based simulations, we confirm the synergistic effect of the epigenetic modulator and that pre-treatment tumor mutational burden, tumor-infiltrating effector T cell (Teff) density, and Teff to regulatory T cell (Treg) ratio are significantly higher in responders, which can be potential biomarkers to be considered in clinical trials. Overall, we present a readily reproducible modular model to conduct in silico virtual clinical trials on patient cohorts of interest, which is a step toward personalized medicine in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Self-citationFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
A methodology for performing global uncertainty and sensitivity analysis in systems biology
Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999
Immune checkpoint inhibitors: recent progress and potential biomarkers
Darvin, P., Toor, S. M., Sasidharan Nair, V., & Elkord, E. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0191-1 · Cited by 2,035
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807 · cited 3×
“Although combination therapy of entinostat and antiPD-1 antibody has shown promising results in patients with anti-PD-1-resistant melanoma and non-small cell lung cancer, the effect of cancer type and patients’ characteristics on the improved efficacy has yet to be determined (Agarwala et al., 2018; Hellmann et al., 2…”
BackgroundKim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676
Romano, E., Kusio-Kobialka, M., Foukas, P. G., Baumgaertner, P., Meyer, C., Ballabeni, P., Michielin, O., Weide, B., Romero, P., & Speiser, D. E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417320112 · Cited by 601
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Arce Vargas, F., Furness, A. J. S., Litchfield, K., Joshi, K., Rosenthal, R., Ghorani, E., Solomon, I., Lesko, M. H., Ruef, N., Roddie, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.010 · Cited by 592 · cited 3×
“In addition, recent studies suggest that Fc domain of the anti-CLTA-4 antibody is required for efficacy in mouse tumor models, which is critical to induce Fc-mediated depletion of regulatory T-cells (Arce Vargas et al., 2018; Ingram et al., 2018; Tang et al., 2018).”
BackgroundYardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Cited by
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01188-4 · Cited by 122
Self-citationA practical guide for the generation of model-based virtual clinical trials
Craig, M., Gevertz, J. L., Kareva, I., & Wilkie, K. P. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1174647 · Cited by 52
An industry perspective on current QSP trends in drug development
Cucurull-Sanchez, L. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09905-y · Cited by 37
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · Handbook of Experimental Pharmacology · doi:10.1007/164_2024_735 · Cited by 6
Self-citation
Metadata
- Authors
- Wang, H., Sové, R. J., Jafarnejad, M., Rahmeh, S., Jaffee, E. M., Stearns, V., Torres, E. T. R., Connolly, R. M., & Popel, A. S.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2020-02-25
- Volume
- 8
- Pages
- 141-141
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W3007686018
- Cited by
- 51
- References
- 17
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. https://app.cochat.ai/papers/10.3389/fbioe.2020.00141
- The paper
- Wang, H., Sové, R. J., Jafarnejad, M., Rahmeh, S., Jaffee, E. M., Stearns, V., Torres, E. T. R., Connolly, R. M., & Popel, A. S. (2020). Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2020.00141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.